(Q73039005)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

L Durelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Oggero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

E Verdun

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G Isoardo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Ricci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

P Barbero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

B Bergamasco

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 September 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Neurological Sciences

31 October 2019

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

37-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

A neurologic rating scale (NRS) for use in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Antibodies to beta-interferons in multiple sclerosis: can we neutralize the controversy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Management of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900361-0

10.1016/S0022-510X(00)00361-0

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11018247%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference